You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

HIGHLIGHTS

CORPORATE

Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017

The prize is awarded to the companies that made the best use of the capital markets

read more 

CORPORATE

Kedrion Biopharma joins Columbia University to celebrate 50 years of Anti-D

Since 1968, billions of babies have been saved from Hemolytic Disease of the Fetus and Newborn

read more 

CORPORATE

Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme

Goal is to improve access to replacement therapies for coagulation disorders in Europe

read more 
  1. PLASMA & BIOTHERAPIES - 05-02-2015

    SIPPET Study: interim analysis confirms the original hypothesis

    The Study on inhibitors in Hemophilia A is safe to continue after Investigators’ Meeting in San Francisco (Dec 2014)

    read more 
  2. EVENTS - 12-01-2015

    Fighting diseases of the new-born: Kedrion attended UENPS conference

    The company also supported a mini-marathon to eradicate HDFN

    read more 
  3. CORPORATE - 26-11-2014

    Kedrion receives the “VedoGreen, Green Excellence in Innovation” Award

    The awards ceremony held in Milan on November 17, during Waiting for Expo 2015, Green Economy 2.0

    read more 

Pages

For more information please contact: pressoffice@kedrion.com